Metformin in Gestational Diabetes: The Offspring Follow-Up (MiG TOFU)
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index; 5 of the 23 sources its claims cite were checked for support.
Abstract
OBJECTIVE: In women with gestational diabetes mellitus, who were randomized to metformin or insulin treatment, pregnancy outcomes were similar (Metformin in Gestational diabetes [MiG] trial). Metformin crosses the placenta, so it is important to assess potential effects on growth of the children. RESEARCH DESIGN AND METHODS: In Auckland, New Zealand, and Adelaide, Australia, women who had participated in the MiG trial were reviewed when their children were 2 years old. Body composition was measured in 154 and 164 children whose mothers had been randomized to metformin and insulin, respectively. Children were assessed with anthropometry, bioimpedance, and dual energy X-ray absorptiometry (DEXA), using standard methods. RESULTS: The children were similar for baseline maternal characteristics and pregnancy outcomes. In the metformin group, compared with the insulin group, children had larger mid-upper arm circumferences (17.2 ± 1.5 vs. 16.7 ± 1.5 cm; P = 0.002) and subscapular (6.3 ± 1.9 vs. 6.0 ± 1.7 mm; P = 0.02) and biceps skinfolds (6.03 ± 1.9 vs. 5.6 ± 1.7 mm; P = 0.04). Total fat mass and percentage body fat assessed by bioimpedance (n = 221) and DEXA (n = 114) were not different. CONCLUSIONS: Children exposed to metformin had larger measures of subcutaneous fat, but overall body fat was the same as in children whose mothers were treated with insulin alone. Further follow-up is required to examine whether these findings persist into later life and whether children exposed to metformin will develop less visceral fat and be more insulin sensitive. If so, this would have significant implications for the current pandemic of diabetes.
Overview
CoChat Summary
TL;DR
In 2-year-old offspring of women with gestational diabetes randomized to metformin or insulin in the MiG trial, metformin-exposed children had larger upper-arm circumference and biceps/subscapular skinfolds, but no difference in total or percentage body fat by DEXA or bioimpedance. The authors conclude the findings are reassuring but that longer follow-up is needed to assess visceral fat and insulin sensitivity.
Key findings
- Among 318 children assessed at age 2 years (154 metformin, 164 insulin), the metformin group had larger mid-upper arm circumference (17.2 ± 1.5 vs. 16.7 ± 1.5 cm; P = 0.002), subscapular skinfold (6.3 ± 1.9 vs. 6.0 ± 1.7 mm; P = 0.02), and biceps skinfold (6.03 ± 1.9 vs. 5.6 ± 1.7 mm; P = 0.04); adjusted P values were 0.005, 0.01, and 0.02, respectively.
- DEXA measures (n = 114; 57 per arm) showed no differences in total fat (2,421 ± 1,002 vs. 2,274 ± 711 g; P = 0.37), abdominal fat (132 ± 73 vs. 131 ± 60 g; P = 0.92), abdominal-to-thigh fat ratio (0.48 ± 0.1 vs. 0.50 ± 0.1; P = 0.33), lean body mass, bone mineral content, FFM, or total fat percentage (16.4 ± 4.9 vs. 16.9 ± 4%; P = 0.34). Bioimpedance (n = 221) also showed no difference in FFM or percentage fat.
- Baseline maternal characteristics and pregnancy outcomes were similar between follow-up groups, including the MiG primary composite of neonatal complications (31.2 vs. 34.7%; P = 0.97) and neonatal unit admission (17.5 vs. 18.3%; P = 0.97). Maternal bioimpedance at follow-up showed higher FFM in the metformin group (51.3 ± 9.21 vs. 48.5 ± 9.09 kg; P = 0.01), but total fat percentage was not different (40.1 ± 7.83 vs. 38.6 ± 7.35%; P = 0.11).
Methods
- Follow-up of women from the MiG trial at Auckland, New Zealand, and Adelaide, Australia, when children were approximately 2 years old; 323 women were seen, and body composition measurements were performed in 318 children (154 metformin, 164 insulin). Assessments included anthropometry, bioimpedance analysis, and DEXA; diet, activity, and neurodevelopmental findings were reported separately.
- Continuous variables were normally distributed and presented as mean ± SD; one-way ANOVA and post hoc t tests were used, with significance at 5%. ANCOVA adjusted for height, weight, and age when examining fat mass and FFM among ethnic groups; additional analyses adjusted for age, sex, ethnicity, and maternal glucose control. Power calculations indicated 240 children (120 per arm) would detect a 2% difference in body fat percent with 97% power, and 37 children per arm would have 80% power.
- DEXA whole-body scans were performed on a Lunar Prodigy 2000 scanner; scans graded 3 for poor quality were excluded. Abdominal and thigh regions of interest were defined by the criteria of Ley et al. A bioimpedance FFM prediction equation was developed using DEXA FFM as the criterion.
Limitations
- Stated: the follow-up rate of the total MiG cohort was low. The follow-up group had fewer Polynesian children (14 vs. 20%; P = 0.02), shorter crown-rump length at birth (33.0 vs. 33.5 cm; P = 0.005), and smaller triceps skinfolds (4.80 vs. 5.15 mm; P = 0.0002) and subscapular skinfolds (4.95 vs. 5.20 mm; P = 0.07) at birth than the total group; otherwise they were representative and the study was adequately powered.
- Stated: central fat measures combined subcutaneous and visceral fat, so further studies are needed to confirm whether metformin-exposed children have less visceral fat. The authors also note there are no other similar studies for comparison and that further follow-up is required to see whether differences persist and to measure visceral/subcutaneous fat and insulin sensitivity.
- Evident from the text: DEXA analysis included only 114 of 318 children (57 per arm) after excluding poor-quality scans, and bioimpedance was performed in 221 children, so body-composition subsamples were smaller than the full follow-up cohort.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 Valid · 0 Not valid · 10 Not checked · 32 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“There are two randomized trials showing that treatment of mild GDM (predominantly with diet) compared with standard pregnancy care was associated with improved pregnancy outcomes (22,23)”
§ Metformin in Gestational Diabetes: The Offspring Follow-Up (MiG TOFU) > CONCLUSIONS
What the sources say
- Supportedcites [22] Crowther, 2005, Effect of treatment of gestational diabetes mellitus on pregnancy outcomes, N Engl J Med source
The design and study population section describes a randomized trial that excluded women with more severe glucose impairment. The interventions section describes dietary advice, glucose monitoring, and insulin as needed; the secondary outcomes section reports that only 20% of the intervention group received insulin and that serious perinatal outcomes fell compared with routine care. This paper supports its role as one of the two trials cited, rather than serving as evidence for both trials. (LLM, conf=0.91)
- Supportedcites [23] Landon, 2009, A multicenter, randomized trial of treatment for mild gestational diabetes, N Engl J Med source
The Methods describe random assignment to usual prenatal care or dietary intervention with insulin if needed. The Results report improved secondary pregnancy outcomes with treatment, and only 37 of 485 treated women required insulin. The Discussion identifies this as one of two trials with findings consistent with the ACHOIS trial, while noting that its primary composite outcome did not improve. Page numbers are not provided in our copy. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“but initial follow-up of children in one trial did not show a significant difference in BMI at 4–5 years of age (24).”
§ Metformin in Gestational Diabetes: The Offspring Follow-Up (MiG TOFU) > CONCLUSIONS
What the sources say
- Supportedcites [24] Gillman, 2010, Effect of treatment of gestational diabetes mellitus on obesity in the next generation, Diabetes Care source
The CONCLUSIONS (p.1 of the section) state that in this follow-up study of children of the ACHOIS randomized trial of treatment for mild GDM, they "did not find that treatment of mild GDM during pregnancy reduced BMI in 4- to 5-year-olds," with an adjusted BMI Z-score difference of 0.08 (95% CI -0.29 to 0.45). RESULTS (Table 2) likewise give null results for continuous BMI Z score and for BMI >= 85th percentile at age 4-5, and the paper frames this as the first such follow-up ("No such studies exist"; longer follow-up needed), consistent with "initial follow-up" and "one trial." (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Reduced insulin sensitivity has been demonstrated in cord blood of infants exposed to maternal hyperglycemia (5).”
§ Metformin in Gestational Diabetes: The Offspring Follow-Up (MiG TOFU) > Abstract > CONCLUSIONS
What the sources say
- Supportedcites [5] Luo, 2010, Maternal glucose tolerance in pregnancy affects fetal insulin sensitivity, Diabetes Care source
The Conclusions report markedly impaired fetal insulin sensitivity in infants of mothers with gestational diabetes. The Primary outcomes section identifies the cord plasma glucose-to-insulin ratio as the study’s indicator of fetal insulin sensitivity, supporting the claim’s reference to cord blood. (LLM, conf=0.92)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“children had larger mid-upper arm circumferences (17.2 ± 1.5 vs. 16.7 ± 1.5 cm; P = 0.002)”
§ Metformin in Gestational Diabetes: The Offspring Follow-Up (MiG TOFU) > Abstract > RESULTS
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“but percentage body fat was not different (Table 3).”
§ Metformin in Gestational Diabetes: The Offspring Follow-Up (MiG TOFU) > RESULTS
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
22 more claims
Create a free account to see all 46 claims and to verify the 18 references still open.
- Probably not a substantial claim. 11
- It may state two separate claims as one. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Body fat percent measured by dual-energy X-ray absorptiometry (DXA) and bioimpedance analysis (BIA) was no different between the treatment arms”
From Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7-9 years of age (2018) · cites this paper as [7]
In the citing paper
“but mid-upper arm circumference was larger, and biceps and subscapular skinfolds were greater in offspring of women randomized to metformin.”
From Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7-9 years of age (2018) · cites this paper as [7]
In the citing paper
“Results of the MiG TOFU reported that infants of diabetic mothers exposed to metformin in utero and examined at 2 years of age may present a reduction in insulin resistance, probably related to an increase in subcutaneous fat [48].”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [48]
In the citing paper
“Moreover, there were no differences in fat measurements, total fat mass, and percentage of body fat(251).”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [251]
In the citing paper
“Those who were exposed to metformin during fetal life had a larger upper arm circumference and bigger subscapular skin folds and biceps, suggesting a better fat distribution than children exposed to insulin(251).”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [251]
Citations
Cites
Effect of In Utero and Early-Life Conditions on Adult Health and Disease
Gluckman, P. D., Hanson, M. A., Cooper, C., & Thornburg, K. L. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708473 · Cited by 3,898 · cited 1×
“It is possible that there are critical windows where interventionmight improve these outcomes (21).”
BackgroundEffect of Treatment of Gestational Diabetes Mellitus on Pregnancy Outcomes
Crowther, C. A., Hiller, J. E., Moss, J. R., McPhee, A. J., Jeffries, W. S., & Robinson, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042973 · Cited by 3,159
Boney, C. M., Verma, A., Tucker, R., & Vohr, B. R. (2005) · Pediatrics · doi:10.1542/peds.2004-1808 · Cited by 2,303
A Multicenter, Randomized Trial of Treatment for Mild Gestational Diabetes
Landon, M. B., Spong, C. Y., Thom, E., Carpenter, M. W., Ramin, S. M., Casey, B., Wapner, R. J., Varner, M. W., Rouse, D. J., Thorp, J. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902430 · Cited by 2,122
Metformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291
Self-citationDabelea, D., Hanson, R. L., Lindsay, R. S., Pettitt, D. J., Imperatore, G., Gabir, M. M., Roumain, J., Bennett, P. H., & Knowler, W. C. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2208 · Cited by 1,277
Klöting, N., Fasshauer, M., Dietrich, A., Kovacs, P., Schön, M. R., Kern, M., Stumvoll, M., & Blüher, M. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00586.2009 · Cited by 856 · cited 3×
“Size and location of fat cells are important predictors of insulin resistance and adverse metabolic consequences of obesity (4,8,12).”
BackgroundSex- and menopause-associated changes in body-fat distribution
Ley, C., Lees, B., & Stevenson, J. (1992) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/55.5.950 · Cited by 733
Clausen, T. D., Mathiesen, E. R., Hansen, T., Pedersen, O., Jensen, D. M., Lauenborg, J., & Damm, P. (2008) · Diabetes Care · doi:10.2337/dc07-1596 · Cited by 724
Sun, S. S., Chumlea, W. C., Heymsfield, S. B., Lukaski, H. C., Schoeller, D., Friedl, K., Kuczmarski, R. J., Flegal, K. M., Johnson, C. L., & Hubbard, V. S. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/77.2.331 · Cited by 692
Research works printed but not linked: 1
- Bristow S. Associations of patterns of daily life, physical fitness and body composition of primary age school children [MPhil thesis online], 2010. Auckland University of Technology. Available from http://aut.researchgateway.ac.nz/handle/10292/1010. Accessed 25 August 2011
Cited by
McIntyre, H. D., Catalano, P., Zhang, C., Desoye, G., Mathiesen, E. R., & Damm, P. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0098-8 · Cited by 1,850
Influence of Maternal Obesity on the Long-Term Health of Offspring
Godfrey, K. M., Reynolds, R. M., Prescott, S. L., Nyirenda, M., Jaddoe, V. W. V., Eriksson, J. G., & Broekman, B. F. P. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30107-3 · Cited by 1,059
A Clinical Update on Gestational Diabetes Mellitus
Sweeting, A., Wong, J., Murphy, H. R., & Ross, G. P. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac003 · Cited by 928
Hod, M., Kapur, A., Sacks, D. A., Hadar, E., Agarwal, M., Di Renzo, G. C., Roura, L. C., McIntyre, H. D., Morris, J. L., & Divakar, H. (2015) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(15)30033-3 · Cited by 767
Gestational Diabetes Mellitus: Risks and Management during and after Pregnancy
Buchanan, T. A., Xiang, A. H., & Page, K. A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.96 · Cited by 718
Metadata
- Authors
- Rowan, J. A., Rush, E. C., Obolonkin, V., Battin, M., Wouldes, T., & Hague, W. M.
- Affiliations
- Department of Obstetrics, National Women’s Health, Auckland, New Zealand
- Auckland University of Technology (NZ)
- University of Auckland (NZ)
- Department of Pediatrics, National Women’s Health, Auckland, New Zealand
- Women's and Children's Hospital (AU)
- Corresponding author
- Rowan, Janet A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-09-15
- Volume
- 34
- Issue
- 10
- Pages
- 2279-2284
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3177748
- OpenAlex
- W2102307174
- Cited by
- 379
- References
- 24
- Citations by year
- 2026: 14 · 2025: 16 · 2024: 16 · 2023: 22 · 2022: 25 · 2021: 36 · 2020: 26 · 2019: 27 · 2018: 50 · 2017: 19 · 2016: 31 · 2015: 28 · 2014: 22 · 2013: 28 · 2012: 16
- FWCI
- 28.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Tuwhera (Auckland University of Technology) (submittedVersion, cc-by-nc-nd)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by-nc-nd)
- ResearchSpace (University of Auckland) (submittedVersion, cc-by)
- Funders
- Auckland University of Technology, New Zealand
- University of Adelaide
- Medical Research Council
- National Health and Medical Research Council
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Birth, Development, and Health
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Keywords
- metformin, gestational diabetes mellitus, insulin therapy, offspring body composition, subcutaneous adipose tissue, fat mass, child growth, prenatal drug exposure, diabetes prevention
- MeSH terms
- Anthropometry, Body Composition, Child, Preschool, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Pregnancy, Prenatal Exposure Delayed Effects, Absorptiometry, Photon, Diabetes, Gestational
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metformin in Gestational Diabetes: The Offspring Follow-Up (MiG TOFU). https://app.cochat.ai/papers/10.2337/dc11-0660
- The paper
- Rowan, J. A., Rush, E. C., Obolonkin, V., Battin, M., Wouldes, T., & Hague, W. M. (2011). Metformin in Gestational Diabetes: The Offspring Follow-Up (MiG TOFU). Diabetes Care. https://doi.org/10.2337/dc11-0660
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
